Pulmatrix (NASDAQ:PULM – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $1.66, FiscalAI reports.
Pulmatrix Price Performance
Shares of PULM traded up $0.09 on Monday, hitting $1.38. The company’s stock had a trading volume of 18,417 shares, compared to its average volume of 39,731. Pulmatrix has a fifty-two week low of $1.06 and a fifty-two week high of $4.98. The company has a market capitalization of $5.04 million, a PE ratio of -1.25 and a beta of 1.95. The company has a 50 day moving average price of $1.46 and a 200 day moving average price of $1.66.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmatrix in a research note on Thursday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Get Our Latest Stock Report on PULM
About Pulmatrix
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies. Its proprietary iSPERSE technology is designed to deliver dry-powder medicines to the lungs, and the company’s work has included treatments for respiratory diseases as well as medicines delivered through the lungs for other conditions. Among its drug candidates, PUR1900 is an inhaled formulation of itraconazole being developed for allergic bronchopulmonary aspergillosis, a lung condition associated with fungal sensitivity.
Read More
- Five stocks we like better than Pulmatrix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
